Boston Scientific expecting 20%-plus sales growth despite near-term absence from stent market.
This article was originally published in The Gray Sheet
BOSTON SCIENTIFIC PROJECTING 20%-PLUS REVENUE GROWTH IN 1998 despite the negative top-line impact likely to stem from the firm's absence from the $1 bil. U.S. coronary stent market. The company, which generated sales of nearly $1.9 bil. in 1997, hopes to enter the stent market by June with the NIR ON Ranger stent system; a premarket approval application was submitted on Jan. 28 ("The Gray Sheet" Feb. 2, In Brief).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.